SEARCH SITE
VIRGINIA LAW PORTAL
- Code of Virginia
- Virginia Administrative Code
- Constitution of Virginia
- Charters
- Authorities
- Compacts
- Uncodified Acts
- RIS Users (account required)
SEARCHABLE DATABASES
- Bills & Resolutions
session legislation - Bill Summaries
session summaries - Reports to the General Assembly
House and Senate documents - Legislative Liaisons
State agency contacts
ACROSS SESSIONS
- Subject Index: Since 1995
- Bills & Resolutions: Since 1994
- Summaries: Since 1994
Developed and maintained by the Division of Legislative Automated Systems.
2015 SESSION
HB 1750 Investigational drugs; expanded access.
Introduced by: Margaret B. Ransone | all patrons ... notes | add to my profiles
SUMMARY AS PASSED: (all summaries)
Expanded access to investigational drugs, biological products, and devices. Provides that a manufacturer of an investigational drug, biological product, or device may make such drug, product, or device available to a person who has a terminal condition when (i) the person has, in consultation with his treating physician, considered all other treatment options currently approved by the U.S. Food and Drug Administration and the treating physician has determined that no reasonable opportunity exists for him to participate in an ongoing clinical trial; (ii) the potential benefits of use of the investigational drug, biological product, or device to treat his terminal condition are greater than the potential risks; (iii) the person has received a recommendation from his treating physician for use of such drug, product, or device for treatment of his terminal condition; and (iv) the person has provided written informed consent. The bill provides that a manufacturer that provides such drug, product, or device may provide the drug, product, or device free of charge or may require the person to pay costs associated with its manufacture and provides that health insurance providers may, but are not required to, provide coverage for costs associated with use of such drug, product, or device. For a health care provider who recommends an investigational drug, biological product, or device and for a manufacturer, distributor, administrator, health care provider, sponsor, or physician who manufactures, supplies, distributes, administers, prescribes, or recommends such drug, product, or device, the bill provides immunity from civil liability and provides that no claim or cause of action shall exist in any state court for claims of property, personal injury, or death caused by, arising out of, or relating to the design, development, clinical testing and investigation, manufacture, labeling, distribution, sale, purchase, donation, dispensing, prescription, recommendation, administration, efficacy, or use of such drug, product, or device to a person who meets eligibility under the law. The bill provides that no health care provider who recommends, prescribes, administers, distributes, or supplies an investigational drug, biological product, or device shall be deemed to have engaged in unprofessional conduct or shall be adversely affected in any decision relating to licensure on such grounds and provides that nothing shall require any person to violate or act in contravention of any federal or state law as such law relates to the prescribing, dispensing, administration, or use of an investigational drug, biological product, or device. This bill is identical to SB 732.
FULL TEXT
- 01/12/15 House: Prefiled and ordered printed; offered 01/14/15 15100033D pdf | impact statement
- 02/02/15 House: Printed as engrossed 15100033D-E pdf | impact statement
- 02/19/15 Senate: Committee substitute printed 15105265D-S1 pdf | impact statement
- 03/06/15 House: Bill text as passed House and Senate (HB1750ER) pdf | impact statement
- 03/26/15 Governor: Acts of Assembly Chapter text (CHAP0656) pdf
AMENDMENTS
HISTORY
- 01/12/15 House: Prefiled and ordered printed; offered 01/14/15 15100033D
- 01/12/15 House: Referred to Committee on Health, Welfare and Institutions
- 01/20/15 House: Assigned HWI sub: Subcommittee #1
- 01/26/15 House: Subcommittee recommends reporting with amendment(s) (11-Y 0-N)
- 01/29/15 House: Reported from Health, Welfare and Institutions with amendments (22-Y 0-N)
- 01/30/15 House: Read first time
- 02/02/15 House: Read second time
- 02/02/15 House: Committee amendments agreed to
- 02/02/15 House: Engrossed by House as amended HB1750E
- 02/02/15 House: Printed as engrossed 15100033D-E
- 02/03/15 House: Read third time and passed House BLOCK VOTE (98-Y 0-N)
- 02/03/15 House: VOTE: BLOCK VOTE PASSAGE (98-Y 0-N)
- 02/04/15 Senate: Constitutional reading dispensed
- 02/04/15 Senate: Referred to Committee on Education and Health
- 02/19/15 Senate: Reported from Education and Health with substitute (14-Y 0-N)
- 02/19/15 Senate: Committee substitute printed 15105265D-S1
- 02/20/15 Senate: Constitutional reading dispensed (38-Y 0-N)
- 02/23/15 Senate: Read third time
- 02/23/15 Senate: Reading of substitute waived
- 02/23/15 Senate: Committee substitute agreed to 15105265D-S1
- 02/23/15 Senate: Passed by for the day
- 02/24/15 Senate: Read third time
- 02/24/15 Senate: Engrossed by Senate - committee substitute HB1750S1
- 02/24/15 Senate: Passed Senate with substitute (39-Y 0-N)
- 02/24/15 House: Placed on Calendar
- 02/25/15 House: Senate substitute agreed to by House 15105265D-S1 (98-Y 0-N)
- 02/25/15 House: VOTE: ADOPTION (98-Y 0-N)
- 03/06/15 House: Enrolled
- 03/06/15 House: Bill text as passed House and Senate (HB1750ER)
- 03/06/15 House: Signed by Speaker
- 03/07/15 Senate: Signed by President
- 03/10/15 House: Enrolled Bill communicated to Governor on 3/10/15
- 03/10/15 Governor: Governor's Action Deadline Midnight, Sunday, March 29, 2015
- 03/26/15 Governor: Approved by Governor-Chapter 656 (effective 7/1/15)
- 03/26/15 Governor: Acts of Assembly Chapter text (CHAP0656)